May 22, 2019
1 min read

FDA grants priority review of canagliflozin for CKD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

James List

The FDA has granted priority review of a supplemental new drug application for Janssen’s Invokana for reducing the risk of ESKD in adults with type 2 diabetes and chronic kidney disease.

Janssen Pharmaceutical Companies said in a press release that if the FDA grants approval of a CKD indication for Invokana (canagliflozin), it will be the first and only drug to treat CKD in patients with type 2 diabetes.

“We are pleased the FDA recognizes the urgency to deliver a novel treatment that can reduce the risk of kidney failure and prevent life-threatening cardiovascular events in people with type 2 diabetes and chronic kidney disease,” James List, MD, PhD, global therapeutic area head of cardiovascular and metabolism at Janssen Research & Development LLC. “This priority review designation brings us one step closer to addressing this major unmet need and providing a new standard of care to those living with this serious condition.”

The application was submitted in March 2019 and was based on a phase 3 CREDENCE renal outcomes study, which was published in the New England Journal of Medicine. Priority review shortens the FDA review period to 6 months compared to 10 months for standard review.

The FDA most recently approved a new indication for Invokana in October 2018 to reduce the risk of major adverse cardiovascular events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes who have established cardiovascular disease.